InterMune Expects to Raise $79.6 Million From Stock Sale

NEW YORK (AP) -- Drugmaker InterMune said Wednesday it expects to raise $79.6 million from a stock offering. The Brisbane, Calif., company said it is selling 6.5 million shares for $13 each.

Shares of InterMune closed at $13.73 Tuesday and the offering is priced at a 5.3% discount.

InterMune said it will use the proceeds to fund the marketing and a U.S. clinical trial of its lung disease drug Esbriet. Esbriet is used to treat a terminal lung disease called idiopathic pulmonary fibrosis, or IPF, which causes inflammation and scarring of the lung. InterMune began the drug in Europe in September 2011. It is available in a number of European countries but has not been approved in the U.S.

The proceeds will also fund work on new formulations of Esbriet and studies of the drug in new indications

The underwriters of the offering will have the option to buy another 975,000 shares to cover any over-allotments, potentially raising InterMune's proceeds.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2715352, ~/Articles/ArticleHandler.aspx, 4/18/2014 11:22:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...